Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy

• Nawara, Hend M.

• Afify, Said M.

• Hassan, Ghmkin

• Zahra, Maram H.

• Seno, Akimasa

• Seno, Masaharu

抄録

Paclitaxel (PTX) is a chemotherapeutical agent commonly used to treat several kinds of cancer. PTX is known as a microtubule-targeting agent with a primary molecular mechanism that disrupts the dynamics of microtubules and induces mitotic arrest and cell death. Simultaneously, other mechanisms have been evaluated in many studies. Since the anticancer activity of PTX was discovered, it has been used to treat many cancer patients and has become one of the most extensively used anticancer drugs. Regrettably, the resistance of cancer to PTX is considered an extensive obstacle in clinical applications and is one of the major causes of death correlated with treatment failure. Therefore, the combination of PTX with other drugs could lead to efficient therapeutic strategies. Here, we summarize the mechanisms of PTX, and the current studies focusing on PTX and review promising combinations.

収録刊行物

• Biomedicines

  Biomedicines 9 (5), 500-, 2021-05-02

  MDPI

キーワード

• paclitaxel
• microtubule targeting agent
• anticancer
• cancer stem cells
• combination therapy

詳細情報

• CRID: 1050288292949028608
• NII論文ID: 120007042394
• ISSN: 22279059
• Web Site: https://ousar.lib.okayama-u.ac.jp/62031
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles